The objective of this study is to investigate the outcome of children 24 months of age or younger (infants) at the time of allogeneic bone marrow transplantation (BMT) for acute leukemia or myelodysplasia. We analyzed the survival rate, prognostic factors, incidences of late sequelae, and immune reconstitution in 22 infants who underwent allogeneic BMT. The 5-year event-free survival estimate was 45.5% (95% confidence interval (CI), 24.4% to 63.3%). Six patients died of transplant-related complications and six died of disease relapse. Remission status at the time of BMT was the most important prognostic factor (P ‫؍‬ 0.005): no patient who received a transplant while their disease was not in remission survived, whereas the 5-year survival estimate for infants who underwent BMT during remission was 56% (95% CI, 31% to 75%). Long-term outcomes in the 10 infant survivors were compared with those of 10 older controls matched for diagnosis, disease status at the time of BMT, calendar year at the time of BMT, and source of stem cells. Immune function 1 year after transplantation and the incidences and spectra of late sequelae were similar for both groups during a median of 3.5 years (range, 1.5 to 7.2 years) of follow-up. Bone Marrow Transplantation (2001) 27, 717-722. Keywords: allogeneic transplantation; infant leukemia; myelodysplastic syndrome; late sequelae
mately 30% when they are treated with conventional chemotherapy. 1, 2 A few studies have proposed the use of bone marrow transplantation (BMT) for the treatment of infants with acute leukemia or myelodysplastic syndrome (MDS). [3] [4] [5] [6] However, allogeneic BMT in the very young remains a clinical challenge. Many factors that can affect the outcome of BMT in older children may differ greatly in infants. Such factors include the biology of the disease, [7] [8] [9] maturity of organ systems, disposition of antineoplastic agents, 10 and susceptibility of the patient to late sequelae. 11 Because very few infants have undergone allogeneic BMT, little information exists about their outcomes. Here we report the treatment sequelae and prognostic factors of 22 infants with acute leukemia or MDS who received allogeneic BMT at the age of 24 months or younger.
Patients and methods

Patients and controls
Review of our database showed that 275 BMTs were performed between January 1993 and April 1999. Of these procedures, 22 involved patients with either acute leukemia or MDS who were younger than 24 months at the time of allogeneic BMT. These 22 patients were the subjects of this investigation. Their characteristics at the time of diagnosis and at the time of BMT are shown in Tables 1 and 2 .
To study whether the incidences of late sequelae and immune reconstitution were different in infant survivors in comparison to older pediatric patients, we then selected from the same database one older control for each infant survivor matched for all of the following four characteristics: diagnosis, disease status at the time of BMT, calendar year at the time of BMT, and source of stem cells (ie matched sibling, mismatched family member, or unrelated volunteer). If more than one control subject fulfilled these criteria, the oldest patient was selected for study so that the observed difference in outcome could be maximized if age at the time of BMT was found to be a significant predictor. At the time of selection of controls, the investigator responsible for the matching did not know their outcomes. The median age for the controls was 9.1 years (range, 3.0 to 15.7 years) at the time of BMT. Their median length of follow-up since BMT was 3.6 years (range, 1.6 to 7.0 years).
Transplantation procedure
The usual order of donor preference, method of HLA typing, conditioning regimen, and graft-versus-host disease (GVHD) prophylaxis used at our center have been described in detail. 12 Briefly, all patients received cytarabine (3 g/m 2 , six doses), cyclophosphamide (45 mg/kg, two doses), and total-body irradiation (total 12 Gy in eight fractions). Anti-T cell antibodies and rabbit complement were used to deplete grafts of T cells from unrelated donors or mismatched family donors. Two days before transplantation, all recipients received cyclosporin at a dosage that was adjusted to achieve plasma concentrations of 250-350 ng/ml. Because marrow from matched siblings was not T cell-depleted, patients given matched sibling marrow received additional prophylaxis with a short course of methotrexate.
Follow-up procedures for survivors
The routine follow-up procedures for long-term survivors at our institution have been described previously. 11, 13 Briefly, after completion of therapy, remission and immune status and late effects of treatment are comprehensively assessed at least annually in our BMT annual follow-up clinic. During each clinic visit, patients or parents complete a four-page questionnaire eliciting information such as medical status and academic progress. All survivors routinely undergo audiography, chest radiography, echocardiography, electrocardiography, urinalysis, and determination of antibody titers against common childhood vaccine antigens, blood cell counts, creatinine clearance, immunoglobulin levels, liver function, serum electrolytes, thyroid function, serum concentrations of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3), at least annually, regardless of symptoms. Other laboratory tests are performed on the basis of clinical findings and the results of the questionnaires. All surviving recipients of allogeneic bone marrow transplants were also evaluated annually by a dentist, an ophthalmologist, and a psychologist at our institution.
14 At the time of this report, all 20 infant survivors or older controls had undergone this routine testing within the last year. The median length of follow-up since BMT for the survivors was 3.5 years (range, 1.5 to 7.2 years).
Statistical analysis
We used the following formula to calculate height z scores: (survivor's height Ϫ mean height of persons of the same sex and age) Ϭ standard deviation (s.d.) of height for persons of the same sex and age. 15 A similar formula was used to calculate weight z scores. The day of granulocyte engraftment was defined as the first of 3 consecutive days in which the patient's absolute granulocyte count exceeded 500/mm 3 . We used the Kaplan-Meier method 16 to calculate the probability of survival estimates. The log-rank test 17 was used to compare survival functions for categorical variables, whereas the Cox proportional hazards model 18 was used to compare survival functions for continuous variables. We use the Wilcoxon rank-sum test to compare the medians for continuous outcome variables, and the chisquare test or Fisher's exact test for categorical outcome variables.
Results
Engraftment and acute GVHD
In all 22 patients, neutrophil engraftment was achieved at a median of 18 days after BMT (range, 13-46 days). Severe (grade II-IV) acute GVHD developed in five of the 22 infants, one subsequently died of GVHD.
719 Table 3 Causes of death (Table 3 ). All six patients with disease that relapsed after BMT died of progressive disease.
Prognostic factors
Remission status at the time of BMT was a significant prognostic factor (P ϭ 0.005, Figure 1 ). None of the infants who underwent BMT while their disease was not in remission survived. In contrast, the 5-year survival estimate for infants who received transplants while their disease was remission was 56% (95% CI, 31%-75%). Other factors, including sex, WBC count at the time of diagnosis, disease type (ie lymphoid or myeloid disease), history of extramedullary disease, presence of 11q23 abnormalities, and source of stem cells, were not significant predictors of survival outcome (all P Ͼ 0.12).
Late sequelae
Late complications were evaluated in the 10 infant survivors and were compared with 10 older controls during a median of 3.5 years of follow-up after BMT (range 1.5 to 7.2 years). The median height z scores of the infant recipients and of the older patients decreased at similar rates after (Figure 2a) . The changes in weight z scores were also similar between the two groups ( Figure 2b) . One of the infant recipients and two of the older recipients have growth hormone deficiency requiring growth hormone supplementation (P ϭ 0.58).
The incidence of hypothyroidism was similar between the two groups (four of the 10 infant recipients and six of the 10 older pediatric patients, P ϭ 0.66). One older recipient had ACTH deficiency requiring corticosteroid replacement therapy. Most of the infant recipients were too young to be evaluated for pubertal development. In one infant recipient, precocious puberty developed and required treatment with a gonadotropin-releasing hormone analog. Hypogonadism requiring sex hormone therapy was found in another infant recipient and in six of the 10 older recipients.
Review of the answers to the annual questionnaires and of psychology reports showed that seven of the 10 infant recipients and eight of the 10 older patients had no neurocognitive deficits (P ϭ 0.61). Two infant recipients and one older patient had a seizure disorder and moderate to severe mental retardation. One infant recipient and one older patient had an attention-deficit disorder. One infant recipi- ent and one older patient had a hearing deficit that was treated with an amplification device. The median left ventricular shortening fractions immediately before BMT were 37.5% for the infants (range, 32% to 42%) and 36% for the older patients (range, 32% to 41%). The median shortening fractions at the time of last follow-up examination were 38.5% for the infant recipients (range, 34% to 42%) and 38.5% for the older patients (range, 35% to 43%) (P ϭ 0.22). Except for one older pediatric patient who required long-term antihypertensive therapy for radiation nephritis, the other 19 survivors had normal blood pressure, serum electrolyte concentrations, and creatinine values at the time of the last follow-up examination.
One of the 10 infant recipients and two of the 10 older recipients had cataracts that were identified by ophthalmologic examination. One older recipient had limited chronic GVHD of the skin.
Immune functions
The immune functions of all 20 survivors were evaluated 1 year after transplantation. The total numbers of B-lymphocyte (CD19 ϩ ), NK cell (CD16 ϩ and CD56 ϩ ), T-lymphocytes (CD3 ϩ ), CD4 ϩ lymphocytes, and CD8 ϩ lymphocytes were similar between the two groups (all P Ͼ 0.10), although the CD4 ϩ cell counts tended to be higher in the infant recipients, whereas the CD8 ϩ cell counts tended to be higher in the older patients (Figure 3a) . The ratio of CD4 ϩ cells to CD8 ϩ cells was inverted in five of the 10 older patients but only in one of the 10 infant recipients (P ϭ 0.05).
Concentrations of IgG, IgM, and IgA were similar between the infant recipients and the older patients ( Figure  3b ) (all P Ͼ 0.36). The percentages of infant recipients and of older patients with protective levels of antibodies to common vaccine antigens were also similar (Figure 3c) : most of the patients had protective levels of antibodies against diphtheria, tetanus, and rubella; but most of the patients lacked immunity against polio, measles, and mumps virus. All of the survivors lacked protective levels of antibody against pertussis.
Discussion
The similarities and differences in outcomes of infants and of older pediatric patients with acute leukemia or MDS who undergo allogeneic BMT have not been established. In this study, we found that the overall 5-year EFS estimate for the infants was 45.5% (95%CI, 24.4%-63.3%). This survival rate is similar to that of older patients transplanted in our center using identical strategies of BMT, 12 and to those reported in infant recipients (range, 30% to 60%) transplanted in other centers. [3] [4] [5] [6] 19 Similar to other reports, infants with myeloid malignancies have similar survival rate to infants with lymphoid malignancies, 3, 19 although small numbers of patients in these studies preclude definitive conclusion. Half of the incidences of death (6/12) in this study were attributable to transplant-related toxicity and the other half (6/12) to relapse, a distribution similar (c) Percentages of infant recipients and of older patients with protective levels of antibodies against diphtheria (D), tetanus (T), pertussis (P), poliovirus (polio), measles (M), mumps (Mu), and rubella (R). The quantity of the samples was inadequate in some patients for all assays. The total number of evaluable patients is shown above each bar.
to that of older patients transplanted in our center using identical strategies of BMT. 12 Of note is that remission status at the time of BMT was the most important prognostic factor. None of the infants who underwent BMT while their disease was not in remission survived. This result suggests that induction of a solid remission before transplantation in the very young should be an important focus in future studies. 20 Optimization of conditioning 21 and posttransplantation therapy 22 may also improve outcome. New approaches under investigation include use of monoclonal antibodies, 23 monitoring of minimal residual disease 24 and chimerism status, 25 and use of immunotherapy after BMT. [26] [27] [28] As expected, the WBC count at the time of diagnosis was high, and CNS disease and 11q23 abnormalities were common in this cohort of infants. 1, 7 These prognostic factors that were significant in prior studies of conventional chemotherapy at our institution 2, 29 were not important in predicting outcome after BMT. Our results suggest that the in vivo response to induction chemotherapy (ie remission status) is more important than any biologic surrogate features in the prediction of the success of BMT for infants.
Late sequelae after BMT for children have been welldocumented, especially those associated with conditioning regimens using total-body irradiation. 13, 30 Total-body irradiation should therefore be avoided, provided that survival is not compromised. 31 Very few studies have focused on the effects of BMT and irradiation in the rare population of survivors of infant leukemia. 5, 11, 32 We have previously described the late effects in a relatively large cohort of 34 patients who survived for more than 5 years after the diagnosis of infant leukemia. 11 Growth and neurocognitive problems were more common in the group who received BMT and irradiation than in the group who received chemotherapy alone. However, it has not been determined whether late sequelae of BMT are more common and more severe in infants than in older pediatric patients who received similar transplants. We systematically evaluated all 10 infant survivors for late complications in comparison to 10 older matched controls. Intensive surveillance testing of all survivors was performed regardless of symptoms. Because our infants and older pediatric patients were matched for many characteristics, pretransplantation treatment, strategies of BMT, duration of follow-up, and tools for evaluation were similar for the two groups. During a median of 3.5 years of follow-up after BMT (range, 1.5 to 7.2 years), we found that the incidence and severity of late sequelae were similar between the younger and older survivors. However, longer follow-up in larger controlled cohorts is clearly necessary to identify developmentally dependent late complications that may have a long latency period. 13, 30, 32 Unfortunately, there are few survivors of infant leukemia after BMT, and a controlled prospective cohort study of the late effects of BMT in infants would take more than 20 years if follow-up extended to adulthood.
Very little information exists about the reconstitution of the immune system in infants after allogeneic BMT. In this study, we found that at 1 year after BMT, the overall immune status of the infant recipients and of the older patients was similar. Prior studies have shown that if the recipients are not immunized before BMT, donor-derived antibody production is not maintained; in most cases, clinically significant antibody levels are no longer detectable 1 year after BMT. 33, 34 In our study, although the infants were only partially immunized before BMT (unlike the older Bone Marrow Transplantation patients who had received all four doses of DTP vaccine), most infant recipients had protective levels of antibody against diphtheria and tetanus 1 year after BMT. In contrast, protective levels of antibody against pertussis were not detected in any of the infant recipients and older patients 1 year after BMT. Similar to the immune responses to bacterial vaccines, vaccination-induced immunity to viral diseases (eg measles, mumps, and rubella) varied. These results underscore the biologic heterogeneity of B cell immunity to specific vaccine antigens and the clinical importance of reimmunization with common childhood vaccines after BMT. 35 The effects of high-dose chemotherapy and total-body irradiation on thymic function of the very young are largely unknown. 36 In the present study, we found that the ratio of CD4 ϩ cells to CD8 ϩ cells was normal in 90% of the infant recipients, but was inverted in half of the older pediatric patients. This result suggests that like adult recipients, many older children have a relatively reduced capacity to produce new CD4 ϩ lymphocytes after BMT; this reduction in capacity may be a possible secondary effect caused by the BMT-induced acceleration of the normal thymic aging process. 37, 38 In infant recipients who were partially immunized, the sustained production of antibody to specific vaccine antigen may be related not only to the helper effects by the thymus-dependent regeneration of CD4 ϩ T lymphocytes, but also by the relatively large numbers of NK cells found in these infants (Figure 3a) . 39, 40 This study has several limitations. First, the size of the cohort and the duration of follow-up are limited. Second, although this study is tightly controlled for internal validity, the external generalizability remains unproven. Third, the retrospective design creates specific problems of incomplete surveillance and noncompliance with recommended follow-up studies. Propitiously, all of the survivors in our study had undergone comprehensive evaluation within 1 year of this analysis.
In summary, this study found that the outcomes of infants younger than 2 years at the time of BMT are similar to those of older pediatric patients. The considerations to treat the very young with BMT should include disease status, if a suitable donor is available. Future strategies should focus on control of disease relapse, because disease recurrence remains a common cause of treatment failure after BMT in the very young. Continuous intensive surveillance and intervention of late sequelae is important to improve the quality of life for many long-term survivors.
